A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican) and early elimination of cyclosporine (Sandimmun Neoral) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy.

Trial Profile

A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican) and early elimination of cyclosporine (Sandimmun Neoral) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Everolimus (Primary) ; Antithymocyte globulin; Ciclosporin; Corticosteroids; Mycophenolate mofetil
  • Indications Heart transplant rejection
  • Focus Therapeutic Use
  • Acronyms SCHEDULE
  • Sponsors Novartis Healthcare; Novartis Norge; Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2018 Results of 3 years follow up assessing the effect of everolimus vs calcineurin inhibitors on left ventricular mass in heart transplant patients presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 14 Apr 2018 Results of the Schedule trial after 6 years presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 14 Apr 2018 Results assessing the effect of everolimus versus Calcineurin Inhibitors (CNI) on Quality of Life during 5-6 years follow-up after heart transplantation, presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top